IS2654B - Essítalópram hýdróbrómíð og aðferð til framleiðslu þess - Google Patents
Essítalópram hýdróbrómíð og aðferð til framleiðslu þessInfo
- Publication number
- IS2654B IS2654B IS7848A IS7848A IS2654B IS 2654 B IS2654 B IS 2654B IS 7848 A IS7848 A IS 7848A IS 7848 A IS7848 A IS 7848A IS 2654 B IS2654 B IS 2654B
- Authority
- IS
- Iceland
- Prior art keywords
- essitalopram
- hydrobromide
- production
- essitalopram hydrobromide
- Prior art date
Links
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Addiction (AREA)
- Anesthesiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200202005 | 2002-12-23 | ||
| PCT/DK2003/000902 WO2004056791A1 (en) | 2002-12-23 | 2003-12-18 | Escitalopram hydrobromide and a method for the preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IS7848A IS7848A (is) | 2005-05-17 |
| IS2654B true IS2654B (is) | 2010-08-15 |
Family
ID=32668635
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IS7848A IS2654B (is) | 2002-12-23 | 2005-05-17 | Essítalópram hýdróbrómíð og aðferð til framleiðslu þess |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US20040167209A1 (enExample) |
| EP (1) | EP1578738B1 (enExample) |
| JP (2) | JP4658613B2 (enExample) |
| KR (1) | KR20050086933A (enExample) |
| CN (1) | CN100349885C (enExample) |
| AR (1) | AR042652A1 (enExample) |
| AT (1) | ATE388947T1 (enExample) |
| AU (1) | AU2003287919B2 (enExample) |
| BR (1) | BR0317623A (enExample) |
| CA (1) | CA2511142A1 (enExample) |
| CY (1) | CY1107451T1 (enExample) |
| DE (1) | DE60319739T2 (enExample) |
| DK (1) | DK1578738T3 (enExample) |
| EA (1) | EA013116B1 (enExample) |
| EG (1) | EG24729A (enExample) |
| ES (1) | ES2298595T3 (enExample) |
| IL (1) | IL169125A0 (enExample) |
| IS (1) | IS2654B (enExample) |
| ME (1) | MEP5808A (enExample) |
| MX (1) | MXPA05005772A (enExample) |
| MY (1) | MY135468A (enExample) |
| NO (1) | NO20053595L (enExample) |
| NZ (1) | NZ540281A (enExample) |
| PE (1) | PE20040924A1 (enExample) |
| PL (1) | PL378275A1 (enExample) |
| PT (1) | PT1578738E (enExample) |
| RS (1) | RS51092B (enExample) |
| TW (1) | TW200501943A (enExample) |
| UA (1) | UA80170C2 (enExample) |
| UY (1) | UY28148A1 (enExample) |
| WO (1) | WO2004056791A1 (enExample) |
| ZA (1) | ZA200504109B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR0317623A (pt) * | 2002-12-23 | 2005-11-29 | Lundbeck & Co As H | Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram |
| US20050137255A1 (en) * | 2002-12-23 | 2005-06-23 | H. Lundbeck A/S | Crystalline escitalopram hydrobromide and methods for preparing the same |
| NZ549100A (en) * | 2004-03-05 | 2010-02-26 | Lundbeck & Co As H | Crystalline composition containing escitalopram oxalate |
| TWI358407B (en) | 2005-06-22 | 2012-02-21 | Lundbeck & Co As H | Crystalline base of escitalopram and orodispersibl |
| US7834201B2 (en) | 2005-06-22 | 2010-11-16 | H. Lundbeck A/S | Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base |
| US20070112075A1 (en) * | 2005-10-14 | 2007-05-17 | Forest Laboratories, Inc. | Stable pharmaceutical formulations containing escitalopram and bupropion |
| EP1954257A4 (en) * | 2005-10-14 | 2009-05-20 | Lundbeck & Co As H | METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION |
| TW200812993A (en) * | 2006-05-02 | 2008-03-16 | Lundbeck & Co As H | New uses of escitalopram |
| JP5501615B2 (ja) * | 2006-07-11 | 2014-05-28 | 田辺三菱製薬株式会社 | モルホリン化合物の塩 |
| WO2008059514A2 (en) * | 2006-07-31 | 2008-05-22 | Cadila Healthcare Limited | Process for preparing escitalopram |
| FR3006594A1 (fr) * | 2013-06-11 | 2014-12-12 | Sorin Crm Sas | Microsonde implantable de detection/stimulation incorporant un agent anti-inflammatoire |
| CN108976188B (zh) * | 2017-06-05 | 2022-12-06 | 上海奥博生物医药股份有限公司 | 一种艾司西酞普兰双羟萘酸盐新的制备方法 |
| RU2020111694A (ru) * | 2017-10-09 | 2021-11-12 | Тева Фармасьютикал Индастриз Лтд. | Новые соли и твердые формы эсциталопрама |
| EP4277661A1 (en) | 2021-01-18 | 2023-11-22 | Anton Frenkel | Pharmaceutical dosage form |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US34712A (en) * | 1862-03-18 | James h | ||
| GB1526331A (en) * | 1976-01-14 | 1978-09-27 | Kefalas As | Phthalanes |
| GB8419963D0 (en) * | 1984-08-06 | 1984-09-12 | Lundbeck & Co As H | Intermediate compound and method |
| GB8814057D0 (en) * | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
| ATE230738T1 (de) * | 1998-10-20 | 2003-01-15 | Lundbeck & Co As H | Verfahren zur herstellung von citalopram |
| AR021155A1 (es) * | 1999-07-08 | 2002-06-12 | Lundbeck & Co As H | Tratamiento de desordenes neuroticos |
| PT1298124E (pt) * | 1999-10-25 | 2007-05-31 | Lundbeck & Co As H | Método para a preparação de citalopram |
| US6977306B2 (en) * | 2000-05-02 | 2005-12-20 | Sumitomo Chemical Company, Limited | Citalopram hydrobromide crystal and method for crystallization thereof |
| JP2002020379A (ja) * | 2000-05-02 | 2002-01-23 | Sumika Fine Chemicals Co Ltd | シタロプラム臭化水素酸塩の結晶およびその結晶化方法 |
| IES20010693A2 (en) * | 2000-08-10 | 2002-07-10 | Lundbeck & Co As H | Pharmaceutical composition containing citalopram |
| WO2002046340A1 (de) * | 2000-12-04 | 2002-06-13 | Dr. Frische Gmbh | Verfahren zur herstellung von fettsaüreestern |
| MXPA03008777A (es) * | 2001-05-01 | 2004-02-12 | Lundbeck & Co As H | El uso de escitalopram enantiomericamente puro. |
| AR034612A1 (es) * | 2001-06-25 | 2004-03-03 | Lundbeck & Co As H | Proceso para la preparacion del citalopram racemico y/o del s- o r-citalopram mediante la separacion de una mezcla de r- y s-citalopram |
| BR0317623A (pt) * | 2002-12-23 | 2005-11-29 | Lundbeck & Co As H | Escitalopram, composição farmacêutica, e, uso de hidrobrometo de escitalopram |
| US20050174782A1 (en) * | 2003-03-25 | 2005-08-11 | Chapman Leonard T. | Flashlight |
-
2003
- 2003-12-18 BR BR0317623-1A patent/BR0317623A/pt not_active IP Right Cessation
- 2003-12-18 PL PL378275A patent/PL378275A1/pl not_active Application Discontinuation
- 2003-12-18 DK DK03779759T patent/DK1578738T3/da active
- 2003-12-18 RS YUP-2005/0487A patent/RS51092B/sr unknown
- 2003-12-18 MX MXPA05005772A patent/MXPA05005772A/es active IP Right Grant
- 2003-12-18 CN CNB2003801063775A patent/CN100349885C/zh not_active Expired - Fee Related
- 2003-12-18 ES ES03779759T patent/ES2298595T3/es not_active Expired - Lifetime
- 2003-12-18 EA EA200501046A patent/EA013116B1/ru not_active IP Right Cessation
- 2003-12-18 CA CA002511142A patent/CA2511142A1/en not_active Abandoned
- 2003-12-18 JP JP2004561083A patent/JP4658613B2/ja not_active Expired - Lifetime
- 2003-12-18 PT PT03779759T patent/PT1578738E/pt unknown
- 2003-12-18 UA UAA200506077A patent/UA80170C2/uk unknown
- 2003-12-18 EP EP03779759A patent/EP1578738B1/en not_active Expired - Lifetime
- 2003-12-18 WO PCT/DK2003/000902 patent/WO2004056791A1/en not_active Ceased
- 2003-12-18 AU AU2003287919A patent/AU2003287919B2/en not_active Ceased
- 2003-12-18 NZ NZ540281A patent/NZ540281A/en not_active Application Discontinuation
- 2003-12-18 KR KR1020057011704A patent/KR20050086933A/ko not_active Ceased
- 2003-12-18 DE DE60319739T patent/DE60319739T2/de not_active Expired - Lifetime
- 2003-12-18 ME MEP-58/08A patent/MEP5808A/xx unknown
- 2003-12-18 AT AT03779759T patent/ATE388947T1/de not_active IP Right Cessation
- 2003-12-22 TW TW092136380A patent/TW200501943A/zh unknown
- 2003-12-22 MY MYPI20034949A patent/MY135468A/en unknown
- 2003-12-22 AR ARP030104777A patent/AR042652A1/es unknown
- 2003-12-23 US US10/746,913 patent/US20040167209A1/en not_active Abandoned
- 2003-12-23 UY UY28148A patent/UY28148A1/es not_active Application Discontinuation
-
2004
- 2004-01-05 PE PE2004000013A patent/PE20040924A1/es not_active Application Discontinuation
-
2005
- 2005-05-17 IS IS7848A patent/IS2654B/is unknown
- 2005-05-20 ZA ZA200504109A patent/ZA200504109B/en unknown
- 2005-06-09 IL IL169125A patent/IL169125A0/en unknown
- 2005-06-22 EG EGNA2005000345 patent/EG24729A/xx active
- 2005-07-25 NO NO20053595A patent/NO20053595L/no not_active Application Discontinuation
-
2008
- 2008-05-02 CY CY20081100470T patent/CY1107451T1/el unknown
-
2010
- 2010-10-20 JP JP2010235287A patent/JP2011037893A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1357025T3 (da) | Skæreindretning og fremgangmåde til skæring | |
| DK1440908T3 (da) | Indsats og fremgangsmåde til fremstilling af drikkevarer | |
| DK1539224T3 (da) | Antimikrobielt præparat og fremgangsmåde til anvendelse | |
| DK3417875T3 (da) | Immunglobulinformulering og fremgangsmåde til fremstilling deraf | |
| NO20031776D0 (no) | Null-boringskomplettering og produksjonssystem | |
| NO20031775D0 (no) | Oppblåsbar pakning og fremgangsmåte | |
| DK1448865T3 (da) | Udtræksstige og tilhörende produktionsfremgangsmåder | |
| DK3246399T3 (da) | Alfavirus-partikler og fremgangsmåder til fremstilling | |
| DK3144240T3 (da) | Stabelbar pakning og fremgangsmåde til tilvejebringelse heraf | |
| DK1667986T3 (da) | Acetonesolvat af dimethoxydocetaxel og fremgangsmåde til fremstilling heraf | |
| NO20044915L (no) | C-aryl-glukosid SGLT2 inhibitorer og metode | |
| BR0308115B1 (pt) | artigo de calÇado e mÉtodo de fabricaÇço de artigo de calÇado | |
| DE60319787D1 (de) | Montageverfahren und -vorrichtung | |
| IS7977A (is) | Samsetningar og aðferð til samsettra meðferðar | |
| IS8204A (is) | Tæki og aðferð til að hluta niður | |
| IS7600A (is) | Aðferð til að stuðla að reykbindindi | |
| IS2654B (is) | Essítalópram hýdróbrómíð og aðferð til framleiðslu þess | |
| DK1601744T3 (da) | Forgasningsapparat og fremgangsmåde | |
| IS8082A (is) | Inndælingarbúnaður án nálar og aðferð til inndælingar | |
| NO20051875D0 (no) | Kjoleror og fremgangsmate for bruk av dette | |
| DK1563110T3 (da) | Svejsbart konstruktionsstålemne og fremgangsmåde til fremstilling heraf | |
| NO20043505L (no) | Rorelement, samt anordning og fremgangsmate for tilvirkning | |
| DK1359593T3 (da) | SPM-sensor og fremgangsmåde til dens fremstilling | |
| DK1563109T3 (da) | Svejsbart konstruktionsstålemne og fremgangsmåde til fremstilling heraf | |
| DK1786680T3 (da) | Beskyttet hætteglas og fremgangsmåde til fremstilling heraf |